Covid-19 vaccine AZD1222 clinical trials resumed in the UK
On 6 September, the standard review process triggered a voluntary pause to vaccination across all global trials to allow review of safety data by independent committees, and international
Johnson & Johnson has submitted a biologics license application (BLA) to the US Food and Drug Administration (FDA) for the approval of nipocalimab, aimed at treating individuals with generalied myasthenia gravis (gMG).
Dupixent, a fully-human monoclonal antibody, blocks the signalling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins. The regulator has provided breakthrough therapy device designation based on data from
Terns recently completed a Phase 1 clinical study of TERN-201, which demonstrated that single and multiple oral administrations of TERN-201 were well tolerated with no significant safety findings
Deliveries would be starting by the end of 2020, subject to clinical success and regulatory authorization. The companies will now enter into contract negotiations with the European Commission.
The FDA-approved strength for both COPD and asthma is fluticasone furoate / umeclidinium / vilanterol 100/62.5/25mcg. There is an additional strength for asthma alone which is fluticasone furoate
Cheplapharm is a specialty pharmaceutical company headquartered in Germany with a 25-year history of successfully acquiring, integrating and growing pharmaceutical products. Takeda will receive an upfront payment of